Decoy Therapeutics (NASDAQ: DCOY) sets July 14, 2026 annual shareholder meeting and proposal deadlines
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Decoy Therapeutics Inc. set July 14, 2026 as the date of its 2026 Annual Meeting of Stockholders. Stockholders of record at the close of business on May 22, 2026 will be entitled to receive notice of and vote at the meeting.
Because this meeting date is more than 30 days later than the prior year’s annual meeting, the company is resetting shareholder proposal and director nomination deadlines. Under Rule 14a-8 and the company’s bylaws, shareholder proposals and director nominations must be received by May 29, 2026 at the company’s Houston, Texas headquarters.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.08, 8.01
2 items
Item 5.08
Shareholder Director Nominations
Governance
Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Annual meeting date: July 14, 2026
Record date: May 22, 2026
Proposal deadline: May 29, 2026
+1 more
4 metrics
Annual meeting date
July 14, 2026
Date of 2026 Annual Meeting of Stockholders
Record date
May 22, 2026
Shareholders of record on this date may vote
Proposal deadline
May 29, 2026
Deadline for Rule 14a-8 proposals and advance notice business
Board action date
May 12, 2026
Date the Board established the 2026 annual meeting date
Key Terms
Rule 14a-8, Amended and Restated Bylaws, advance notice procedures, universal proxy rules, +1 more
5 terms
Rule 14a-8 regulatory
"In accordance with Rule 14a-8 under the Exchange Act (“Rule 14a-8”), if a stockholder wishes to present a proposal..."
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
Amended and Restated Bylaws regulatory
"Any such proposal must ... otherwise comply with, the Company’s Amended and Restated Bylaws (as amended, the “Bylaws”)."
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
advance notice procedures regulatory
"In accordance with the advance notice procedures set forth in the Bylaws, if a stockholder wishes to bring business..."
universal proxy rules regulatory
"In addition to satisfying the procedures set forth in the Bylaws, to comply with the universal proxy rules under the Exchange Act..."
Universal proxy rules require that when shareholders vote to elect directors in a contested election, the proxy card mailed to investors can include candidates nominated by both the company and dissident shareholders, letting investors mix and match their choices on a single ballot. This matters to investors because it makes their vote more flexible and easier to use, like replacing separate lists with one common ballot, which can influence who controls the board and the company’s future direction.
Rule 14a-19 regulatory
"must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act, no later than May 29, 2026..."
Rule 14a-19 is a U.S. Securities and Exchange Commission rule that governs how independent proxy advisory firms produce and distribute voting recommendations for shareholders. It requires these advisers to provide companies with notice of their recommendations and a chance to respond, and to disclose certain conflicts; think of it as a referee ensuring both sides see a game plan before fans cast votes. Investors care because proxy advisers influence voting outcomes and corporate governance, so the rule affects transparency, potential bias, and the reliability of guidance that many investors rely on when voting shares.
FAQ
When is Decoy Therapeutics (DCOY) holding its 2026 annual meeting?
Decoy Therapeutics will hold its 2026 Annual Meeting of Stockholders on July 14, 2026. The specific time, location, and additional details will be provided in the company’s proxy statement to be filed with the SEC before the meeting.
What are the universal proxy notice requirements for Decoy Therapeutics’ 2026 meeting?
Shareholders planning to solicit proxies for director nominees other than Decoy Therapeutics’ nominees must provide notice with the information required by Rule 14a-19 by May 29, 2026, which aligns with the later of the specified calendar tests in the filing.
Why did Decoy Therapeutics (DCOY) announce new proposal deadlines for the 2026 annual meeting?
The 2026 annual meeting date differs by more than 30 days from the prior year’s meeting, so Decoy Therapeutics is updating shareholders on new deadlines in accordance with Rule 14a-5(f) and its bylaws to govern proposals and nominations.